유전자 벡터 시장 : 벡터별, 용도별, 질병별, 최종사용자별, 세계 예측(2023-2032년)

Global Gene Vector Market size will expand considerably through 2032. Growing number of clinical trials will pave the way for industry growth. Many clinical trials explore the potential of combination therapies, where gene therapy is combined with other treatment modalities such as chemotherapy, radiation therapy, or immunotherapy. These combination approaches often involve the use of multiple gene vectors to deliver different therapeutic agents or enhance treatment synergies. The increasing exploration of combination therapies in clinical trials contributes to the higher demand for gene vectors.

The overall gene vector market is classified based on vector, application, diseases, end-user, and region.

Based on the vector, industry share from the lentiviral segment will grow at a substantial CAGR from 2023 to 2032. Increasing investment in gene therapy will generate lucrative opportunities for segment growth. Lentiviral vectors are widely used as vehicles for delivering genes into target cells. They can efficiently transfer genetic material, such as therapeutic genes, to a range of cell types, including non-dividing or slowly dividing cells. This ability makes them valuable in gene therapy, where they are used to treat genetic disorders.

Based on diseases, industry share from the infectious disease segment will grow at a significant CAGR from 2023 to 2032. Growing prevalence of infectious diseases has increased the demand for gene vectors. Gene vectors can be used to develop vaccines against infectious diseases. They can deliver specific antigen genes into host cells, triggering an immune response and the production of protective antibodies. This approach offers advantages such as the ability to generate a broad immune response, including cellular immunity, and the potential to rapidly develop vaccines for emerging infectious diseases.

Based on the end-user, industry value from the CROs segment will register significant gains through 2032. Increasing number of CROs is contributing to segment growth. Moreover, rising efforts by these organizations toward the development of gene therapies are further creating a notable impetus for segment expansion. CROs conduct preclinical studies using gene vectors to assess the safety and efficacy of potential gene therapies or gene-based treatments.

Regionally, the Asia Pacific gene vector market share will grow at an exponential CAGR from 2023 to 2032. Growing occurrence of infectious disorders such as HIV/AIDS has increased the demand for gene vectors in the region. Moreover, rapidly expanding healthcare infrastructure is further contributing to regional growth. As per IBEF, in the Union Budget 2023-24, the government of India awarded USD 10.76 billion to the Ministry of Health and Family Welfare.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Data Sources
  • 1.4.1 Secondary
    • 1.4.1.1 Paid sources
    • 1.4.1.2 Public sources
  • 1.4.2 Primary

Chapter 2 Executive Summary

• 2.1 Gene vector 360 degree synopsis, 2018 - 2032
• 2.2 Business trends
• 2.3 Vector type trends
• 2.4 Application trends
• 2.5 Disease trends
• 2.6 End user trends

Chapter 3 Gene Vector Market Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of genetic disorders, cancer, and infectious diseases
    • 3.2.1.2 Development of more advanced gene editing technologies
    • 3.2.1.3 Increasing demand for personalized medicine
    • 3.2.1.4 Increase in R&D investments for the development of gene therapy
    • 3.2.1.5 Ongoing research into viral vector-based gene therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of gene therapies
    • 3.2.2.2 Challenges associated with regulatory approval of gene vectors development
• 3.3 Growth potential analysis
  • 3.3.1 By vector type
  • 3.3.2 By application
  • 3.3.3 By disease
  • 3.3.4 By end user
• 3.4 COVID- 19 impact analysis
• 3.5 Technological analysis
• 3.6 Regulatory landscape
  • 3.6.1 U.S.
  • 3.6.2 Europe
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Market share analysis , 2022
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Gene Vector Market Size and Forecast, By Vector Type (USD Million)

• 5.1 Key trends, by vector type
• 5.2 Plasmid DNA
• 5.3 Retroviral
• 5.4 Lentiviral
• 5.5 Adenoviral
• 5.6 Adeno-associated viral
• 5.7 Other vector types

Chapter 6 Gene Vector Market Size and Forecast, By Application (USD Million)

• 6.1 Key trends, by application
• 6.2 Gene therapy
• 6.3 Vaccinology
• 6.4 Other applications

Chapter 7 Gene Vector Market Size and Forecast, By Disease (USD Million)

• 7.1 Key trends, by disease
• 7.2 Oncology
• 7.3 Genetic disorders
• 7.4 Infectious diseases
• 7.5 Other diseases

Chapter 8 Gene Vector Market Size and Forecast, By End-user (USD Million)

• 8.1 Key trends, by end-user
• 8.2 CDMOs
• 8.3 Pharmaceutical and biotechnology companies
• 8.4 Research institutes
• 8.5 CROs

Chapter 9 Gene Vector Market Size and Forecast, By Region (USD Million)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia and New Zealand
  • 9.4.5 Rest of Asia pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 MEA
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

• 10.1 Lonza
• 10.2 Merck KGaA
• 10.3 Thermo Fisher Scientific Inc.
• 10.4 Oxford Biomedica
• 10.5 Cobra Biologics
• 10.6 Novasep
• 10.7 Spark Therapeutics
• 10.8 Kaneka Eurogentec
• 10.9 Finvector Vision Therapies
• 10.10 Brammer Bio
• 10.11 Cell and Gene Therapy Catapult
• 10.12 FUJIFILM Diosynth Biotechnologies
• 10.13 uniQure N.V.